Nanologica AB (publ)

Stockholm Stock Exchange NICA.ST

Nanologica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2023: -105.92%

Nanologica AB (publ) Return on Capital Employed (ROCE) is -105.92% for the year ending December 31, 2023, a -197.35% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Nanologica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -35.62%, a 28.21% change year over year.
Nanologica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -49.62%, a -240.87% change year over year.
Nanologica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -14.56%, a 79.53% change year over year.
Nanologica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -71.11%, a 6.61% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: NICA.ST

Nanologica AB (publ)

CEO	Mr. Andreas Bhagwani
IPO Date	Oct. 30, 2015
Location	Sweden
Headquarters	Forskargatan 20G
Employees	16
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Composite Materials Petrochemicals Pharmaceuticals Plastics Pollution Treatment

Description

Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.

Key trends

Past 5 years